David A. Siegel Crispr Therapeutics Ag Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Two Sigma Advisers, LP holds 797,200 shares of CRSP stock, worth $29.7 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
797,200
Previous 84,800
840.09%
Holding current value
$29.7 Million
Previous $3.34 Million
712.95%
% of portfolio
0.06%
Previous 0.01%
Shares
21 transactions
Others Institutions Holding CRSP
# of Institutions
479Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$378 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$226 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$141 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$103 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$94.6 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.9B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....